We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Nitrazine in the Treatment of ALS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04950647
Recruitment Status : Recruiting
First Posted : July 6, 2021
Last Update Posted : July 6, 2021
Sponsor:
Collaborator:
West China Hospital
Information provided by (Responsible Party):
Peking University Third Hospital

Brief Summary:
To evaluate the trend of safety and effectiveness of Nitroketazine tablets for ALS patients, and to explore the best effective dose.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: Nitrofurazone Group 1 Drug: Nitroketazine Group 2 Drug: placebo group Phase 2

Detailed Description:
This trial was a randomized, double-blind, placebo-controlled parallel design. Patients with ALS were selected by inclusion exclusion criteria, and then randomly assigned to receive either the experimental drug or placebo. Test group 1: Nitroketazine tablet 600mg group (Nitroketazine 300mg tablet x2 + placebo 300mg tablet x2 each time; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x6 tablets + placebo 100mg tablets x6 tablets can be taken instead). Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100 mg tablets x12 tablets can be taken instead). Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300 mg tablets, they may take placebo 100mg tablets x 12 tablets instead). Usage: Oral administration, twice a day, once in the morning and once in the evening (or the interval between two medication is 28h), at least 1" hour before meal (21 h before meal) on an empty stomach or at least 2 hours after meal (22h after meal) on an empty stomach, 180±3 days. Eligible subjects will start treatment on Day 1 after randomization, and visit the study center at the end of 1, 3, and 6 (or when they quit the study midway) for safety and efficacy checks. Telephone interviews were conducted at the end of the seventh day of treatment, the end of the second month, the end of the fourth month, the end of the fifth month of treatment, and the second week after the end of the sixth month of treatment. A total of 150 ALS patients were planned to be enrolled, with 50 patients in each group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : December 31, 2022


Arm Intervention/treatment
Experimental: Test group 1
Nitroketazine tablet 600 mg group
Drug: Nitrofurazone Group 1
Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.

Experimental: Test group 2
Nitroketazine tablets 1200 mg group
Drug: Nitroketazine Group 2
Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).

Placebo Comparator: Control group
placebo group
Drug: placebo group
Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).




Primary Outcome Measures :
  1. ALSFRS-R score [ Time Frame: Treatment day 180 ]
    ALSFRS -r score difference between the difference in value relative to the baseline group;


Secondary Outcome Measures :
  1. grip strength [ Time Frame: Treatment day 180 ]
    Intergroup differences in grip strength relative to baseline difference



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 45-70, gender unlimited (including 45 and 70);
  2. diagnoses in accordance with the confirmed and proposed ALS diagnostic standards ofthe Revised World Federation of Neurology (1998);
  3. The duration of disease from onset to randomization of subjects is less than 2 years;
  4. Before randomization, ALSFRS-R scores were ≥2 points, and respiratory function items were 4 points;
  5. ALSFRS-R decreased by 1-4 points in screening period 3A (≥1 and lt; 4);
  6. Random pre-respiratory function Forced Vital Capacity (%FVC) ≥80%;
  7. Understand and abide by the test procedures, participate voluntarily, and sign the informed consent (the informed consent should be signed by the person or the guardian voluntarily).

Exclusion Criteria:

  1. Familial ALS (judged by family history);
  2. Patients with significant cognitive impairment (MMSE: illiteracy group < 19 points, elementary school. 22 points, S26 points in the junior high school and above group (more than 8 years of education);
  3. obvious dysphagia;
  4. Severe renal insufficiency: creatinine clearance. 30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency;
  5. Severe liver function impairment: ALT, AST> 3 times the upper limit of normal value, or other known liver diseases such as acute or chronic active hepatitis, cirrhosis, etc.;
  6. In the screening stage, patients with heart failure who developed acute myocardial infarction or underwent interventional therapy within the last 6 months (grade II1-IV according to NYHA);
  7. Complicated with malignant tumors, serious diseases of blood, digestion or other systems.
  8. Allergic to experimental drugs or ligustrazine;
  9. Pregnancy and lactation;
  10. Participated in, or is participating in, other clinical trials within 30 days prior to screening;
  11. The investigator did not consider it appropriate to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04950647


Contacts
Layout table for location contacts
Contact: Dongsheng Fan +86 13701023871 dsfan@sina.com

Locations
Layout table for location information
China, Beijing
Peking University Third Hospital Recruiting
Beijing, Beijing, China, 100098
Contact: Dongsheng Fan         
Sponsors and Collaborators
Peking University Third Hospital
West China Hospital
Investigators
Layout table for investigator information
Principal Investigator: Dongsheng Fan Peking University Third Hospital
Layout table for additonal information
Responsible Party: Peking University Third Hospital
ClinicalTrials.gov Identifier: NCT04950647    
Other Study ID Numbers: D2020109
First Posted: July 6, 2021    Key Record Dates
Last Update Posted: July 6, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Nitrofurazone
Anti-Infective Agents